<DOC>
	<DOCNO>NCT00945906</DOCNO>
	<brief_summary>Congenital deficiency factor XIII extremely rare inherit disorder associate potentially life-threatening bleeding . Factor XIII Concentrate give patient whose blood lack factor XIII . Factor XIII Concentrate work assist blood usual clotting process , thereby prevent bleed . In study , patient treat FXIII Concentrate ( Human ) follow closely determine receive dose FXIII Concentrate ( Human ) best minimize chance bruise bleed . The purpose study provide FXIII Concentrate ( Human ) patient product become commercially available United States .</brief_summary>
	<brief_title>An Open Enrollment Study Factor XIII Concentrate Subjects With Congenital Factor XIII Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Factor XIII Deficiency</mesh_term>
	<criteria>Written inform consent/assent study participation obtain undergo study specific procedure Diagnosed congenital FXIII deficiency require prophylactic treatment Males females age Diagnosis acquire FXIII deficiency Administration FXIIIcontaining product , include blood transfusion blood product , within 3 week prior Baseline/Day 0 Visit Any known congenital acquire coagulation disorder congenital FXIII deficiency Use IMP within 4 week prior Baseline/Day 0 Visit Female subject childbearing potential use , willing use , medically reliable method contraception entire duration study Suspected inability ( e.g. , language problem ) unwillingness comply study procedure history noncompliance Any laboratory find medical condition , opinion Investigator , would put subject subject 's disease management risk</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Hereditary Factor XIII deficiency</keyword>
	<keyword>Factor XIII</keyword>
</DOC>